Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐N‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anticanc...
Gespeichert in:
Veröffentlicht in: | Journal of mass spectrometry. 2011-10, Vol.46 (10), p.1039-1045 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1045 |
---|---|
container_issue | 10 |
container_start_page | 1039 |
container_title | Journal of mass spectrometry. |
container_volume | 46 |
creator | Sala, Federica Bagnati, Renzo Livi, Valeria Cereda, Roberta D'Incalci, Maurizio Zucchetti, Massimo |
description | E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐N‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐performance liquid chromatography–tandem mass spectrometry method was developed and validated to measure the drug in human plasma on the basis of simple protein precipitation with methanol after addition of deuterated E‐3810 as internal standard. The method requires a small volume of sample (100 µl) and is rapid and selective, allowing good resolution of peaks in 5 min. It is sensitive, precise, and accurate, with overall precision, expressed as CV%, always ≤7.1%, accuracy in the range 92.7%–104.4%, and high recovery, close to 100%. The limit of detection is 0.01 ng/ml, and the lower limit of quantitation is 2.0 ng/ml. The assay was validated in the range from the lower limit of quantitation up to 500.0 ng/ml. This is the first method developed and validated for analyzing E‐3810 in human plasma. The method has been successfully applied to study E‐3810 pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase I trial. Copyright © 2011 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/jms.1985 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_900627621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>900627621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4215-f8c4ac14d9d44fead7120a7dba8e6b06f369ce2b3ccb38c31346c93b5a85052d3</originalsourceid><addsrcrecordid>eNp9ktGO1CAUhhujcdfVxCcw3Bi96Qq0pfRSd9ZRs2qMGr1rKJxO2S3QBbo6r-0TSJ1x9kpvgBw-_v8P52TZY4JPCcb0xaUJp6Th1Z3smOCG5Q3n_O5yrllekbo8yh6EcIkxbpqS3c-OKMWEshofZ79WcAOjmwzYiIRV6EaMWomonUWuRwINejPkE_jeeSOsBDTq61krJAfvjIhu48U0bPOY3oJBRoSAwgQypluIfovSOjiF0nMUB0AKInij7cFhKVqXMiBtB93pmMDF2G6024CFoAM6zwtOcALQMKcQaBpFMOJPXB0DEtM0arlTTIxActQ2FUY0DSKllu5KW4haohBntX2Y3evFGODRfj_Jvr4-_3L2Jr_4uH579vIilyUlVd5zWQpJStWosuxBqJpQLGrVCQ6sw6wvWCOBdoWUXcFlQYqSyaboKsErXFFVnGTPdrqTd9czhNgaHSSMo7Dg5tA2GDNaM0oS-fy_JMGUckYa2tyi0rsQPPTt5LURfpugdpmFNs1Cu8xCQp_sVefOgDqAf5ufgKd7QIT0W71P_dXhlitrzOtqEcp33A89wvafhu2795_3xntehwg_D7zwVy2ri7pqv31Yt-tPfLX-vl61r4rf2UngTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1022861929</pqid></control><display><type>article</type><title>Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Sala, Federica ; Bagnati, Renzo ; Livi, Valeria ; Cereda, Roberta ; D'Incalci, Maurizio ; Zucchetti, Massimo</creator><creatorcontrib>Sala, Federica ; Bagnati, Renzo ; Livi, Valeria ; Cereda, Roberta ; D'Incalci, Maurizio ; Zucchetti, Massimo</creatorcontrib><description>E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐N‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐performance liquid chromatography–tandem mass spectrometry method was developed and validated to measure the drug in human plasma on the basis of simple protein precipitation with methanol after addition of deuterated E‐3810 as internal standard. The method requires a small volume of sample (100 µl) and is rapid and selective, allowing good resolution of peaks in 5 min. It is sensitive, precise, and accurate, with overall precision, expressed as CV%, always ≤7.1%, accuracy in the range 92.7%–104.4%, and high recovery, close to 100%. The limit of detection is 0.01 ng/ml, and the lower limit of quantitation is 2.0 ng/ml. The assay was validated in the range from the lower limit of quantitation up to 500.0 ng/ml. This is the first method developed and validated for analyzing E‐3810 in human plasma. The method has been successfully applied to study E‐3810 pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase I trial. Copyright © 2011 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1076-5174</identifier><identifier>ISSN: 1096-9888</identifier><identifier>EISSN: 1096-9888</identifier><identifier>DOI: 10.1002/jms.1985</identifier><identifier>PMID: 22012670</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Analysis ; Angiogenesis Inhibitors - blood ; Biological and medical sciences ; Calibration ; Chromatography ; Chromatography, High Pressure Liquid - economics ; Chromatography, High Pressure Liquid - methods ; Drugs ; E-3810 ; FGFR/VEGFR inhibitor ; General pharmacology ; Growth factors ; HPLC-MS/MS ; Human ; Humans ; Inhibitors ; Limit of Detection ; Liquids ; Mass spectrometry ; Medical sciences ; Methyl alcohol ; Naphthalenes - blood ; Neoplasms - blood ; pharmacokinetics ; Pharmacology. Drug treatments ; phase I study ; Quinolines - blood ; Rabeprazole ; Tandem Mass Spectrometry - economics ; Tandem Mass Spectrometry - methods</subject><ispartof>Journal of mass spectrometry., 2011-10, Vol.46 (10), p.1039-1045</ispartof><rights>Copyright © 2011 John Wiley & Sons, Ltd.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4215-f8c4ac14d9d44fead7120a7dba8e6b06f369ce2b3ccb38c31346c93b5a85052d3</citedby><cites>FETCH-LOGICAL-c4215-f8c4ac14d9d44fead7120a7dba8e6b06f369ce2b3ccb38c31346c93b5a85052d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjms.1985$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjms.1985$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24708755$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22012670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sala, Federica</creatorcontrib><creatorcontrib>Bagnati, Renzo</creatorcontrib><creatorcontrib>Livi, Valeria</creatorcontrib><creatorcontrib>Cereda, Roberta</creatorcontrib><creatorcontrib>D'Incalci, Maurizio</creatorcontrib><creatorcontrib>Zucchetti, Massimo</creatorcontrib><title>Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study</title><title>Journal of mass spectrometry.</title><addtitle>J. Mass. Spectrom</addtitle><description>E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐N‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐performance liquid chromatography–tandem mass spectrometry method was developed and validated to measure the drug in human plasma on the basis of simple protein precipitation with methanol after addition of deuterated E‐3810 as internal standard. The method requires a small volume of sample (100 µl) and is rapid and selective, allowing good resolution of peaks in 5 min. It is sensitive, precise, and accurate, with overall precision, expressed as CV%, always ≤7.1%, accuracy in the range 92.7%–104.4%, and high recovery, close to 100%. The limit of detection is 0.01 ng/ml, and the lower limit of quantitation is 2.0 ng/ml. The assay was validated in the range from the lower limit of quantitation up to 500.0 ng/ml. This is the first method developed and validated for analyzing E‐3810 in human plasma. The method has been successfully applied to study E‐3810 pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase I trial. Copyright © 2011 John Wiley & Sons, Ltd.</description><subject>Analysis</subject><subject>Angiogenesis Inhibitors - blood</subject><subject>Biological and medical sciences</subject><subject>Calibration</subject><subject>Chromatography</subject><subject>Chromatography, High Pressure Liquid - economics</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Drugs</subject><subject>E-3810</subject><subject>FGFR/VEGFR inhibitor</subject><subject>General pharmacology</subject><subject>Growth factors</subject><subject>HPLC-MS/MS</subject><subject>Human</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Limit of Detection</subject><subject>Liquids</subject><subject>Mass spectrometry</subject><subject>Medical sciences</subject><subject>Methyl alcohol</subject><subject>Naphthalenes - blood</subject><subject>Neoplasms - blood</subject><subject>pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>phase I study</subject><subject>Quinolines - blood</subject><subject>Rabeprazole</subject><subject>Tandem Mass Spectrometry - economics</subject><subject>Tandem Mass Spectrometry - methods</subject><issn>1076-5174</issn><issn>1096-9888</issn><issn>1096-9888</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ktGO1CAUhhujcdfVxCcw3Bi96Qq0pfRSd9ZRs2qMGr1rKJxO2S3QBbo6r-0TSJ1x9kpvgBw-_v8P52TZY4JPCcb0xaUJp6Th1Z3smOCG5Q3n_O5yrllekbo8yh6EcIkxbpqS3c-OKMWEshofZ79WcAOjmwzYiIRV6EaMWomonUWuRwINejPkE_jeeSOsBDTq61krJAfvjIhu48U0bPOY3oJBRoSAwgQypluIfovSOjiF0nMUB0AKInij7cFhKVqXMiBtB93pmMDF2G6024CFoAM6zwtOcALQMKcQaBpFMOJPXB0DEtM0arlTTIxActQ2FUY0DSKllu5KW4haohBntX2Y3evFGODRfj_Jvr4-_3L2Jr_4uH579vIilyUlVd5zWQpJStWosuxBqJpQLGrVCQ6sw6wvWCOBdoWUXcFlQYqSyaboKsErXFFVnGTPdrqTd9czhNgaHSSMo7Dg5tA2GDNaM0oS-fy_JMGUckYa2tyi0rsQPPTt5LURfpugdpmFNs1Cu8xCQp_sVefOgDqAf5ufgKd7QIT0W71P_dXhlitrzOtqEcp33A89wvafhu2795_3xntehwg_D7zwVy2ri7pqv31Yt-tPfLX-vl61r4rf2UngTA</recordid><startdate>201110</startdate><enddate>201110</enddate><creator>Sala, Federica</creator><creator>Bagnati, Renzo</creator><creator>Livi, Valeria</creator><creator>Cereda, Roberta</creator><creator>D'Incalci, Maurizio</creator><creator>Zucchetti, Massimo</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>L7M</scope><scope>7X8</scope></search><sort><creationdate>201110</creationdate><title>Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study</title><author>Sala, Federica ; Bagnati, Renzo ; Livi, Valeria ; Cereda, Roberta ; D'Incalci, Maurizio ; Zucchetti, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4215-f8c4ac14d9d44fead7120a7dba8e6b06f369ce2b3ccb38c31346c93b5a85052d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Analysis</topic><topic>Angiogenesis Inhibitors - blood</topic><topic>Biological and medical sciences</topic><topic>Calibration</topic><topic>Chromatography</topic><topic>Chromatography, High Pressure Liquid - economics</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Drugs</topic><topic>E-3810</topic><topic>FGFR/VEGFR inhibitor</topic><topic>General pharmacology</topic><topic>Growth factors</topic><topic>HPLC-MS/MS</topic><topic>Human</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Limit of Detection</topic><topic>Liquids</topic><topic>Mass spectrometry</topic><topic>Medical sciences</topic><topic>Methyl alcohol</topic><topic>Naphthalenes - blood</topic><topic>Neoplasms - blood</topic><topic>pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>phase I study</topic><topic>Quinolines - blood</topic><topic>Rabeprazole</topic><topic>Tandem Mass Spectrometry - economics</topic><topic>Tandem Mass Spectrometry - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sala, Federica</creatorcontrib><creatorcontrib>Bagnati, Renzo</creatorcontrib><creatorcontrib>Livi, Valeria</creatorcontrib><creatorcontrib>Cereda, Roberta</creatorcontrib><creatorcontrib>D'Incalci, Maurizio</creatorcontrib><creatorcontrib>Zucchetti, Massimo</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of mass spectrometry.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sala, Federica</au><au>Bagnati, Renzo</au><au>Livi, Valeria</au><au>Cereda, Roberta</au><au>D'Incalci, Maurizio</au><au>Zucchetti, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study</atitle><jtitle>Journal of mass spectrometry.</jtitle><addtitle>J. Mass. Spectrom</addtitle><date>2011-10</date><risdate>2011</risdate><volume>46</volume><issue>10</issue><spage>1039</spage><epage>1045</epage><pages>1039-1045</pages><issn>1076-5174</issn><issn>1096-9888</issn><eissn>1096-9888</eissn><abstract>E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐N‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐performance liquid chromatography–tandem mass spectrometry method was developed and validated to measure the drug in human plasma on the basis of simple protein precipitation with methanol after addition of deuterated E‐3810 as internal standard. The method requires a small volume of sample (100 µl) and is rapid and selective, allowing good resolution of peaks in 5 min. It is sensitive, precise, and accurate, with overall precision, expressed as CV%, always ≤7.1%, accuracy in the range 92.7%–104.4%, and high recovery, close to 100%. The limit of detection is 0.01 ng/ml, and the lower limit of quantitation is 2.0 ng/ml. The assay was validated in the range from the lower limit of quantitation up to 500.0 ng/ml. This is the first method developed and validated for analyzing E‐3810 in human plasma. The method has been successfully applied to study E‐3810 pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase I trial. Copyright © 2011 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>22012670</pmid><doi>10.1002/jms.1985</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1076-5174 |
ispartof | Journal of mass spectrometry., 2011-10, Vol.46 (10), p.1039-1045 |
issn | 1076-5174 1096-9888 1096-9888 |
language | eng |
recordid | cdi_proquest_miscellaneous_900627621 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Analysis Angiogenesis Inhibitors - blood Biological and medical sciences Calibration Chromatography Chromatography, High Pressure Liquid - economics Chromatography, High Pressure Liquid - methods Drugs E-3810 FGFR/VEGFR inhibitor General pharmacology Growth factors HPLC-MS/MS Human Humans Inhibitors Limit of Detection Liquids Mass spectrometry Medical sciences Methyl alcohol Naphthalenes - blood Neoplasms - blood pharmacokinetics Pharmacology. Drug treatments phase I study Quinolines - blood Rabeprazole Tandem Mass Spectrometry - economics Tandem Mass Spectrometry - methods |
title | Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A43%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20a%20high-performance%20liquid%20chromatography-tandem%20mass%20spectrometry%20method%20for%20the%20determination%20of%20the%20novel%20inhibitor%20of%20angiogenesis%20E-3810%20in%20human%20plasma%20and%20its%20application%20in%20a%20clinical%20pharmacokinetic%20study&rft.jtitle=Journal%20of%20mass%20spectrometry.&rft.au=Sala,%20Federica&rft.date=2011-10&rft.volume=46&rft.issue=10&rft.spage=1039&rft.epage=1045&rft.pages=1039-1045&rft.issn=1076-5174&rft.eissn=1096-9888&rft_id=info:doi/10.1002/jms.1985&rft_dat=%3Cproquest_cross%3E900627621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1022861929&rft_id=info:pmid/22012670&rfr_iscdi=true |